Literature DB >> 11750322

The evolving role of tor inhibitors for individualizing posttransplant immunosuppression.

M I Lorber1, G P Basadonna, A L Friedman, K M Lorber, M J Bia, R Formica, J D Smith.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11750322     DOI： 10.1016/s0041-1345(01)02311-9

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  2 in total

1.  Therapeutic effect of a new immunosuppressive agent, everolimus, on interleukin-10 gene-deficient mice with colitis.

Authors:  C Matsuda; T Ito; J Song; T Mizushima; H Tamagawa; Y Kai; Y Hamanaka; M Inoue; T Nishida; H Matsuda; Y Sawa
Journal:  Clin Exp Immunol       Date:  2007-05       Impact factor: 4.330

Review 2.  Clinical pharmacokinetics of everolimus.

Authors:  Gabriele I Kirchner; Ivo Meier-Wiedenbach; Michael P Manns
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.